Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Operating Expenses (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Operating Expenses data on record, last reported at $36.1 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 6.83% year-over-year to $36.1 million; the TTM value through Sep 2025 reached $141.9 million, down 26.22%, while the annual FY2024 figure was $161.8 million, 64.07% down from the prior year.
  • Operating Expenses reached $36.1 million in Q3 2025 per SGMO's latest filing, roughly flat from $36.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $139.9 million in Q1 2023 and bottomed at $33.5 million in Q4 2024.
  • Average Operating Expenses over 5 years is $69.8 million, with a median of $72.6 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: skyrocketed 90.39% in 2023, then tumbled 71.29% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $67.9 million in 2021, then increased by 21.71% to $82.6 million in 2022, then decreased by 22.42% to $64.1 million in 2023, then tumbled by 47.67% to $33.5 million in 2024, then rose by 7.73% to $36.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $36.1 million in Q3 2025, $36.2 million in Q2 2025, and $36.1 million in Q1 2025.